查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1579395

自体干细胞/非干细胞治疗市场：按类型、适应症和最终用户划分 - 2025-2030 年全球预测

Autologous Stem Cell & Non-Stem Cell Therapies Market by Type (Autologous Non-Stem Cells, Autologous Stem Cells), Indication (Cancer, Cardiovascular Disease, Neurodegenerative Disorders), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

自体干细胞/非干细胞治疗市场2023年估值为46.7亿美元，预计2024年将达到52.8亿美元，复合年增长率为14.45%，至2030年将达到120.1亿美元。

在自体和非自体干细胞治疗领域，患者自身的细胞被用来治疗和预防疾病。这些治疗方法具有广泛的应用，从再生医学到癌症和自体免疫疾病的治疗。需要这些治疗方法是因为可以减少排斥反应、降低併发症风险以及个人化治疗方法，与传统方法相比具有显着优势。主要最终用途领域包括医疗机构、研究机构和生技公司。市场成长受到细胞处理技术进步、研究经费增加以及人口老化导致的未满足医疗需求增加的显着影响。此外，核准创新治疗方法的监管支持进一步支持了这些治疗方法的采用。开拓先进的细胞处理技术和进入医疗保健系统不足的新兴市场存在商机。可客製化治疗方法和技术共用的合作研究也提供了良好的前景。然而，市场面临治疗成本高、监管障碍以及细胞收集和应用方面的伦理问题等挑战。此外，治疗的扩充性和一致的品管增加了复杂性。创新的最佳途径包括研究提高细胞活力和寿命、增强传递机制以及优化储存解决方案。此外，利用机器学习在治疗方法开发和患者结果评估中进行预测建模可以提供竞争优势。整体而言，自体和非自体干细胞治疗市场是一个充满活力的市场，其特点是快速的技术创新和有希望的成长机会，但必须仔细掌握监管环境和伦理考量。与监管机构和相关人员的积极合作有助于克服障碍并促进更顺利的市场进入和扩张。

主要市场统计
基准年[2023] 46.7亿美元
预测年份 [2024] 52.8亿美元
预测年份 [2030] 120.1亿美元
复合年增长率（%） 14.45%

市场动态：快速发展的自体干细胞和非干细胞治疗市场的关键市场洞察

自体干细胞和非干细胞治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 慢性病盛行率增加
    • 再生医学技术的进展
    • 对个人化医疗的认识和接受度不断提高
  • 市场限制因素
    • 由于临床资料有限，家庭疗法的长期有效性尚不确定
  • 市场机会
    • 扩大基因编辑技术研究
    • 政府扶持政策与经费推动自体干细胞应用研发
  • 市场挑战
    • 自体干细胞治疗的严格法规和核准流程

波特的五力：驾驭自体干细胞/非干细胞治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对自体干细胞/非干细胞治疗市场的影响

外部宏观环境因素在塑造自体干细胞和非干细胞治疗市场的动态表现方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解自体干细胞/非干细胞治疗市场的竞争状况

自体干细胞和非干细胞治疗市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵自体干细胞/非干细胞治疗市场供应商绩效评估

FPNV定位矩阵是评估自体干细胞和非干细胞治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，描绘自体干细胞和非干细胞治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，自体干细胞和非干细胞治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病增加
      • 再生医学技术的进展
      • 对个人化医疗的认识和接受度不断提高
    • 抑制因素
      • 有限的临床资料对自体免疫疗法的长期疗效产生了不确定性
    • 机会
      • 扩大基因编辑技术研究
      • 政府扶持政策和经费将促进自体干细胞应用研发
    • 任务
      • 自体干细胞治疗的严格监管障碍和核准流程
  • 市场区隔分析
    • 类型：探讨自体干细胞的进展及其对血液学、心血管和肿瘤学治疗的影响
    • 最终使用者：研究设施对自体干细胞和非干细胞治疗的影响
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章自体干细胞/非干细胞治疗市场：依类型

  • 自体非干细胞
    • CAR-T细胞疗法
    • 肿瘤浸润淋巴细胞
  • 自体干细胞

第七章自体干细胞/非干细胞治疗市场（依适应症）

  • 癌症
  • 心血管疾病
  • 神经退化性疾病
  • 整形外科疾病

第八章自体干细胞/非干细胞治疗市场：依最终用户分类

  • 门诊手术中心
  • 医院
  • 研究设施

第九章 美洲自体干细胞/非干细胞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章 亚太地区自体干细胞/非干细胞治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲自体干细胞/非干细胞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 百时美施贵宝的 Breyanzi 获得 FDA 优先核准，这是一种治疗某些血液癌症的新型 CAR T 细胞疗法
    • FDA核准针对多发性骨髓瘤患者的新干细胞动员疗法
  • 战略分析和建议

公司名单

  • Anterogen Co., Ltd.
  • Bluebird Bio, Inc.
  • Brainstorm Cell Therapeutics, Inc.
  • Caladrius Biosciences, Inc.
  • Castle Creek Biosciences Inc.
  • Cytori Therapeutics Inc.
  • Dendreon Pharmaceuticals LLC
  • Gilead Sciences, Inc.
  • HCA International Limited
  • Hemogenyx Pharmaceuticals PLC
  • Hemostemix Inc.
  • Jasper Therapeutics, Inc.
  • Juventas Therapeutics, Inc.
  • Kolon TissueGene, Inc.
  • Medipost Co., Ltd.
  • NOVADIP Biosciences SA
  • Novartis AG
  • NuVasive, Inc.
  • Opexa Therapeutics, Inc.
  • Regeneus Ltd. by Cambium-Cambium Bio Limited
  • Reliance Life Sciences Pvt. Ltd.
  • Stempeutics Research Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vericel Corporation
Product Code: MRR-030C42D3EDB5

The Autologous Stem Cell & Non-Stem Cell Therapies Market was valued at USD 4.67 billion in 2023, expected to reach USD 5.28 billion in 2024, and is projected to grow at a CAGR of 14.45%, to USD 12.01 billion by 2030.

The field of autologous stem cell and non-stem cell therapies involves using a patient's own cells to treat or prevent diseases. These therapies have broad applications, ranging from regenerative medicine to cancer and autoimmune disorder treatment. The necessity of these therapies stems from their potential for reduced rejection rates, lower risk of complications, and personalized treatment approaches, offering significant advantages over traditional methodologies. Key end-use sectors include healthcare institutions, research organizations, and biotech firms. Market growth is heavily influenced by technological advancements in cell processing, increasing funding for research, and the growing unmet medical needs of aging populations. Moreover, regulatory support in approving innovative therapies is further driving the adoption of these treatment modalities. Opportunities beckon in the development of advanced cell processing techniques and expanding into untapped markets with healthcare system inadequacies. Customizable therapeutic approaches and collaborations for technology sharing also present lucrative prospects. However, the market faces challenges such as high treatment costs, regulatory hurdles, and ethical concerns regarding cell harvesting and application. Moreover, scalability and consistent quality control of therapies add to the complexity. The best paths for innovation include research into improving cell viability and longevity, enhancing delivery mechanisms, and optimizing storage solutions. Additionally, leveraging machine learning for predictive modeling in therapy development and patient outcome assessments can offer competitive advantages. Overall, the market for autologous stem cell and non-stem cell therapies is dynamic, characterized by rapid technological innovations and promising growth opportunities, but requires careful navigation through regulatory landscapes and ethical considerations. Engaging in proactive collaboration with regulatory bodies and stakeholders can help surmount barriers and facilitate smoother market entry and expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 4.67 billion
Estimated Year [2024] USD 5.28 billion
Forecast Year [2030] USD 12.01 billion
CAGR (%) 14.45%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autologous Stem Cell & Non-Stem Cell Therapies Market

The Autologous Stem Cell & Non-Stem Cell Therapies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases
    • Advancements in regenerative medicine technology
    • Rising awareness and acceptance of personalized medicine
  • Market Restraints
    • Limited clinical data creating uncertainty regarding the long-term efficacy of autologous therapies
  • Market Opportunities
    • Expanding research in gene editing technology
    • Supportive government policies and funding boost R&D in autologous stem cell applications
  • Market Challenges
    • Stringent Regulatory hurdles & approval process for autologous stem cell therapies

Porter's Five Forces: A Strategic Tool for Navigating the Autologous Stem Cell & Non-Stem Cell Therapies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autologous Stem Cell & Non-Stem Cell Therapies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autologous Stem Cell & Non-Stem Cell Therapies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autologous Stem Cell & Non-Stem Cell Therapies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autologous Stem Cell & Non-Stem Cell Therapies Market

A detailed market share analysis in the Autologous Stem Cell & Non-Stem Cell Therapies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autologous Stem Cell & Non-Stem Cell Therapies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autologous Stem Cell & Non-Stem Cell Therapies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autologous Stem Cell & Non-Stem Cell Therapies Market

A strategic analysis of the Autologous Stem Cell & Non-Stem Cell Therapies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autologous Stem Cell & Non-Stem Cell Therapies Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Bluebird Bio, Inc., Brainstorm Cell Therapeutics, Inc., Caladrius Biosciences, Inc., Castle Creek Biosciences Inc., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Gilead Sciences, Inc., HCA International Limited, Hemogenyx Pharmaceuticals PLC, Hemostemix Inc., Jasper Therapeutics, Inc., Juventas Therapeutics, Inc., Kolon TissueGene, Inc., Medipost Co., Ltd., NOVADIP Biosciences S.A., Novartis AG, NuVasive, Inc., Opexa Therapeutics, Inc., Regeneus Ltd. by Cambium - Cambium Bio Limited, Reliance Life Sciences Pvt. Ltd., Stempeutics Research Pvt. Ltd., Takeda Pharmaceutical Company Limited, and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Autologous Stem Cell & Non-Stem Cell Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Autologous Non-Stem Cells and Autologous Stem Cells. The Autologous Non-Stem Cells is further studied across Car T Cell Therapies and Tumor Infiltrating Lymphocyte.
  • Based on Indication, market is studied across Cancer, Cardiovascular Disease, Neurodegenerative Disorders, and Orthopedic Diseases.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Research Facilities.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases
      • 5.1.1.2. Advancements in regenerative medicine technology
      • 5.1.1.3. Rising awareness and acceptance of personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Limited clinical data creating uncertainty regarding the long-term efficacy of autologous therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding research in gene editing technology
      • 5.1.3.2. Supportive government policies and funding boost R&D in autologous stem cell applications
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent Regulatory hurdles & approval process for autologous stem cell therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Exploring Advancements in Autologous Stem Cell, Impacts on Hematological, Cardiovascular, and Oncology Treatments
    • 5.2.2. End-User: Impact of Research Facilities in Autologous Stem Cell & Non-Stem Cell Therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type

  • 6.1. Introduction
  • 6.2. Autologous Non-Stem Cells
    • 6.2.1. Car T Cell Therapies
    • 6.2.2. Tumor Infiltrating Lymphocyte
  • 6.3. Autologous Stem Cells

7. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication

  • 7.1. Introduction
  • 7.2. Cancer
  • 7.3. Cardiovascular Disease
  • 7.4. Neurodegenerative Disorders
  • 7.5. Orthopedic Diseases

8. Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Research Facilities

9. Americas Autologous Stem Cell & Non-Stem Cell Therapies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Autologous Stem Cell & Non-Stem Cell Therapies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Autologous Stem Cell & Non-Stem Cell Therapies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Bristol Myers Squibb Gets FDA Fast-Track for New CAR T Cell Therapy Breyanzi to Treat Certain Blood Cancers
    • 12.3.2. FDA Approves New Stem Cell Mobilization Therapy for Multiple Myeloma Patients
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Anterogen Co., Ltd.
  • 2. Bluebird Bio, Inc.
  • 3. Brainstorm Cell Therapeutics, Inc.
  • 4. Caladrius Biosciences, Inc.
  • 5. Castle Creek Biosciences Inc.
  • 6. Cytori Therapeutics Inc.
  • 7. Dendreon Pharmaceuticals LLC
  • 8. Gilead Sciences, Inc.
  • 9. HCA International Limited
  • 10. Hemogenyx Pharmaceuticals PLC
  • 11. Hemostemix Inc.
  • 12. Jasper Therapeutics, Inc.
  • 13. Juventas Therapeutics, Inc.
  • 14. Kolon TissueGene, Inc.
  • 15. Medipost Co., Ltd.
  • 16. NOVADIP Biosciences S.A.
  • 17. Novartis AG
  • 18. NuVasive, Inc.
  • 19. Opexa Therapeutics, Inc.
  • 20. Regeneus Ltd. by Cambium - Cambium Bio Limited
  • 21. Reliance Life Sciences Pvt. Ltd.
  • 22. Stempeutics Research Pvt. Ltd.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CAR T CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ORTHOPEDIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RESEARCH FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023